This article is part of a special supplement published by Nephrology News & Issues in the February 2014 issue entitled, "Iron therapy and a quarter century of ESAs: What have we learned?" The ...

Washington, DC - Intravenous iron sucrose therapy as an adjuvant treatment to erythropoiesis-stimulating agents (ESA) can help effectively battle anemia in peritoneal-dialysis (PD) patients and avoid ...

Red blood cell transfusions enhance quality of life for MDS patients but require careful management due to potential risks ...

Vascular Calcification mortality non-dialysis CKD Study shows benefit of initiating epoetin beta therapy at hemoglobin levels not less than 10 g/dL in non-dialysis CKD patients. Earlier treatment of ...

Gaithersburg, MD - As a drug class, the erythropoiesis-stimulating agents (ESAs) have been available for the treatment of anemia in patients with chronic kidney disease (CKD) for the better of two ...

statin-therapy_1115 Using statins for more than 3 months was significantly associated with 85% lower odds of ESA hyporesponsiveness in CKD patients. Statin therapy may curb hyporesponsiveness to ...

Iron deficiency is prevalent in patients with chronic kidney disease (CKD), and use of oral and intravenous iron in patients with CKD who do not require dialysis might obviate or delay the need for ...

Please provide your email address to receive an email when new articles are posted on . We learned from the nephrologists that even in what we consider iron-replete patients who are receiving ESAs, ...

In a Japanese study, approximately 1 in 8 CKD patients with anemia failed to respond to darbepoetin alfa therapy. Specific factors may predict better initial response to darbepoetin alfa in patients ...

Expert panelists discuss when it’s appropriate to consider or continue ESA therapy or blood transfusions in patients with MDS. Bruce Feinberg, DO: Amer, invariably, there are patients who aren’t going ...